Closer to patients
faster to recruit

Cardiovascular disease is a huge global problem and creates significant competition for studies. AES has successfully randomized around 36,000 patients, covered more than 800 protocols and supported almost 3,000 sites.

AES Patients has a proven recruiting model that can engage dermatology patients. We’ve already supported almost 500 dermatology protocols and successfully randomized nearly 16,500 patients. 

AES goes beyond traditional targeting to find the right gastroenterology patients for each trial through direct access to pre-qualified candidates. AES specializes in Non-Alcoholic SteatoHepatitis, Non-Alcoholic Fatty Liver Disease, Crohn’s disease and Ulcerative Colitis. 

Patients with rheumatoid arthritis are difficult to recruit, because there is a relatively small population available. AES has access to around 850,000 potential patients already in the proprietary AES database.  

Across our flagship neuroscience sites, AES has conducted over 80 Phase II and Phase III Alzheimer’s Disease/dementia trials during the past five years with access to neurologists at over 30 sites globally. 

AES delivers nearly nine million potential patients across a range of respiratory indications.

With proven ability to engage diverse volunteer and patient populations, a large global footprint and more than 25 years of experience, AES is an ideal partner for biopharmaceutical companies that want certainty for their vaccines trial. 

Our teams have extensive therapeutic and regulatory experience across a broad spectrum of indications that allows us to work at a specialist level. Browse the many additional indications that we work in.